Nasdaq · Healthcare
Vivos Therapeutics, Inc. (VVOS)
As-reported financials and recent SEC filings for Vivos Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$17.4M
Net income
$-21.2M
Net margin
-121.4%
Diluted EPS
$-2.07
ROE
1365.8%
P/E (TTM)
—
Market cap
—
Debt / equity
-0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M |
| Gross profit | $10.5M | $9.0M | $8.3M | — | — |
| Operating income | $-19.9M | $-11.2M | $-17.3M | $-25.0M | $-20.4M |
| Net income | $-21.2M | $-11.1M | $-13.6M | $-23.8M | $-20.3M |
| Diluted EPS | $-2.07 | $-1.11 | $-1.39 | $-3.24 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-25
View on EDGAR →8-K2026-06-16
View on EDGAR →8-K2026-06-16
View on EDGAR →8-K2026-06-08
View on EDGAR →10-Q2026-05-20
View on EDGAR →NT 10-Q2026-05-15
View on EDGAR →SCHEDULE 13G2026-05-15
View on EDGAR →EFFECT2026-05-08
View on EDGAR →Largest Healthcare peers
Go deeper on VVOS
Search Vivos Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.